NextGen Acquires Patent Application for Breast Cancer Stem Cell Treatment

LONDON, UNITED KINGDOM (PINK SHEETS: NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has acquired use, commercialisation and ownership rights of a patent application for the treatment of cancer from Oxon Life Science Inc.

The patent application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are normally resistant to conventional therapies. The cancer stem cell is typically represented as a distinct population of cells within a tumour which may remain even if the rest of the tumour is destroyed, through chemotherapy, or other anti-cancer therapies. This may lead to the subsequent re-occurrence of the cancer at a later date, a relapse, which is devastating for the patient. These cancer stem cells, precursors of cancer, possess certain characteristics, which can be targeted to allow identification.

NextGen CEO, Konstantinos Kardiasmenos, stated, "Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies."

"Acquiring the patent application for this innovative biotechnology is an exciting early step in its progress toward commercialisation," he said.

About NextGen Bioscience Inc.

NextGen is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

At present, NextGen is rapidly building its portfolio of proprietary biotechnology. NextGen's target market --cancer treatments-- is the largest disease market, exploding at a 20% growth rate each year. NextGen's treatment niche is based on recent discoveries that indicate that most tumors may be derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). NextGen has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Statements about NextGen's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. NextGen's actual results could differ materially from expected results. NextGen undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

For more information about NextGen Bioscience Inc., or to schedule an interview with Mr. Kardiasmenos, please contact Investor Relations at [phone] or [e-mail].

Contacts: NextGen Bioscience, Inc. Konstantinos Kardiasmenos [phone] [phone] (FAX) Email: [e-mail] Website: www.nextgenbioscience.com